ArticleOncology letters2026
Endostar combined with docetaxel or cisplatin in the management of malignant ascites through hyperthermic intraperitoneal chemotherapy: A retrospective cohort study.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peritoneal metastases (PM) are a prevalent and treatment-resistant form of recurrence in patients with abdominal tumors. The present study retrospectively examined the clinical performance and potential adverse effects of combining Endostar with docetaxel/cisplatin chemotherapeutic hyperthermic intraperitoneal chemotherapy (HIPEC) for treating malignant ascites (MA). Subjects diagnosed with malignancies confirmed by ascites cell block results and clinical presentations were included within the study, constituting a total of 48 MA cases. The docetaxel group (n=25) was treated with Endostar combined with docetaxel for two cycles. The cisplatin group (n=23) was treated with Endostar combined with cisplatin for two cycles. The objective response rate (ORR; defined as CR + PR), disease control rate (DCR; defined as CR + PR + SD), ascites control time, improvement rate of the Karnofsky Performance Status (KPS) and incidence of major adverse reactions were statistically analyzed. There were no significant differences in the ORR (64.0 vs. 56.5%), DCR (92.0 vs. 91.3%), improvement rate of KPS (48.0 vs. 43.5%) or ascites control time (55 vs. 46 days) between the docetaxel and cisplatin groups (all P>0.05). Renal function impairment developed in 7 patients (30.4%) in the cisplatin group compared with 1 patient (4.0%) in the docetaxel group (P<0.05). Except for renal injury and blood pressure, there were no statistically significant differences in the incidences of other adverse reactions or treatment-related deaths between the two groups. Overall, the combined application of Endostar and docetaxel/cisplatin HIPEC yielded promising clinical outcomes in the treatment of MA, as indicated by high ORRs and DCRs, significantly improving the quality of life for affected individuals. However, it is worth noting that the incidence of nephrotoxicity was higher in the cisplatin treatment group compared with that in the docetaxel treatment group. Therefore, clinicians should be cautious about nephrotoxicity when administering cisplatin in high-risk patients with PM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.